Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of “Moderate Buy” from Analysts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has received a consensus rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $10.6667.

TSHA has been the subject of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Monday, December 29th. Wall Street Zen downgraded shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Chardan Capital reissued a “buy” rating and set a $12.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Finally, Citizens Jmp lifted their price objective on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “market outperform” rating in a report on Wednesday, November 5th.

Taysha Gene Therapies Price Performance

Shares of TSHA opened at $4.57 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.48 and a current ratio of 10.48. Taysha Gene Therapies has a fifty-two week low of $1.05 and a fifty-two week high of $6.02. The firm has a 50-day simple moving average of $5.11 and a 200-day simple moving average of $4.09. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -13.85 and a beta of 1.02.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. On average, equities research analysts anticipate that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Insider Activity at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 26,918 shares of the firm’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $124,091.98. Following the completion of the sale, the insider owned 1,317,389 shares of the company’s stock, valued at approximately $6,073,163.29. This trade represents a 2.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Sean P. Nolan sold 41,312 shares of the company’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $4.61, for a total transaction of $190,448.32. Following the transaction, the chief executive officer directly owned 2,908,257 shares in the company, valued at approximately $13,407,064.77. This trade represents a 1.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 967,140 shares of company stock worth $4,510,613 over the last three months. 3.78% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Pictet Asset Management Holding SA purchased a new stake in Taysha Gene Therapies during the 4th quarter worth about $106,000. Vanguard Group Inc. boosted its stake in shares of Taysha Gene Therapies by 3.3% during the 4th quarter. Vanguard Group Inc. now owns 13,267,805 shares of the company’s stock worth $72,973,000 after purchasing an additional 418,192 shares during the last quarter. NBC Securities Inc. purchased a new stake in shares of Taysha Gene Therapies during the fourth quarter worth about $291,000. Arizona State Retirement System acquired a new position in shares of Taysha Gene Therapies in the fourth quarter valued at approximately $207,000. Finally, Chicago Partners Investment Group LLC lifted its stake in shares of Taysha Gene Therapies by 1.5% during the fourth quarter. Chicago Partners Investment Group LLC now owns 166,541 shares of the company’s stock valued at $916,000 after buying an additional 2,504 shares during the period. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.